Division of Medical Oncology

Noteworthy Publications

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris. Risk Model-Guided Antiemetic Prophylaxis vs Physician’s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2016;2(2):225–31.

Brulé SY, Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51(11):1405–14.

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomized controlled phase 3 trials. Lancet Oncol 2015;16:897–907.

Asmis TR, Febbraro M, Alvarez GG, Spaans JN, Ruta M, Lalany A, Osborne G, Goss GD. A retrospective review of cancer treatments and outcomes among Inuit referred from Nunavut, Canada. Curr Oncol 2015;22(4):246–51

Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. Clin Cancer Res 2015;21(20):4561–8.

Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17(5):577–89.


Key Peer Reviewed Grants

Drs Roanne Segal and Xinni Song (co-investigators): The effects of an online mindfulness-based stress reduction program in cancer survivors with chronic neuropathic pain: A randomized controlled trial. Canadian Cancer Society; PI: Dr Patricia Poulin; 2016–19; Funding: 2016/2017: $112,728

Drs Derek Jonker (chair, GI Committee), Glen Goss (chair: Lung Committee), Scott Laurie (chair: IND Committee) (co-investigators): Canadian Cancer Society Clinical Trials Group: Canadian Cancer Society; PI: Dr. Janet Dancey; 2010–17; $25,586,666 ($5,117,333 each year)

Dr. Derek Jonker (co-investigator): Biotherapeutics for Cancer Treatment (BioCanRx)). Network of Centres of Excellence Canada; PI: Dr John Bell; $25,000,000

Dr. Glen Goss (PI): Canadian Cancer Clinical Trials Network (3CTN); $1,295,000

Dr. Mark Clemons (PI), John Hilton (co-investigator): A randomized trial of individualized care vs standard care for breast cancer patients at high risk for chemotherapy induced nausea and vomiting (the ILIAD study). Canadian Breast Cancer Foundation. $436,120 over 3 years

Dr. Guy Ungerechts: Terry Fox Young Investigator Award. $450,000



The Division of Medical Oncology is a member of the Department of Medicine at The Ottawa Hospital and the University of Ottawa Faculty of Medicine.  The Division provides all medical oncology services to Eastern Ontario with a population of over 1.2 million.

There are currently 22 medical oncologists supported by allied health professionals in tumour-site-specific teams.  The Division has a leading role in conducting local, national and international clinical trials in association with the Ottawa Health Research Institute, and is a major contributor to the research programs of the NCIC Clinical Trials Group.  The Division also fulfills its academic role through undergraduate, postgraduate and continuing medical education activities.


The Division is a leader in education in the undergraduate, postgraduate and accredited continuing medical education. Our division can provide a comprehensive experience in leading edge multidisciplinary care across the full spectrum of tumour sites, including novel therapies through clinical trials. We can offer encounters in both the inpatient and outpatient settings.

In addition to offering educational opportunities to medical students and postgraduate trainees, we have a highly successful medical oncology training program.

For physicians who have completed their medical oncology training, we also offer 1-3 year fellowships (under the direction of Dr Tim Asmis) focused on specific tumor sites (including lung, breast, GI and GU cancers and others), with additional potential opportunities in new drug development and translational research. We welcome inquiries from both Canadian and international trainees.


Research in the Division of Oncology is geared towards improving patient care, extending survival, and ultimately curing patients of their cancer by means of innovative cancer therapies. Through The Ottawa Hospital Cancer Centre, the division conducts between 75 and 100 clinical trials for many different types and stages of cancer.

Patient Care

The Division of Medical Oncology is part of the Ottawa Hospital Cancer Centre and provides a wide range of cancer care and services ranging from prevention/screening, through assessment and treatment, to end of life and survivorship care.

The Ottawa Hospital Cancer Program offers cancer services at The Ottawa Hospital Cancer Centre located at TOH’s General Campus and at the Irving Greenberg Family Cancer Centre located at the Queensway Carleton Hospital.

Recent Notable Honours and Achievements

  • Dr. Rachel Goodwin was winner of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the NCIC CCTG annual meeting (for her contributions to
  • the development and evaluation of new cancer treatments) and of the Conquer Cancer Foundation of ASCO Merit Award at the Gastrointestinal Cancers Symposium (2016)
  • Dr. Tim Asmis has taken on a major provincial leadership role as the OMA Section Chief for Hematology/Medical Oncology.
  • Dr. Paul Wheatley-Price has assumed the role of president of the national patient advocacy group Lung Cancer Canada.
  • Dr. Tina Hsu obtained grant funding for and co-lead organization of the first Canadian Network for Cancer and Aging Meeting.